However, the apparent lack of GIP efficacy in patient with T2D coupled with the obesity protective phenotype of GIPR knockout mice, initially discouraged the development of GIPR agonists for diabetes therapy and even suggested that development of GIPR antagonists might be expedient. Here, GIPR is linked to obesity disorder.